Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter
October 22, 2024 16:45 ET
|
Ocean Biomedical, Inc.
PROVIDENCE, Rhode Island, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on October 16, 2024, it received a Staff Determination Letter from The Nasdaq...
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses
October 01, 2024 08:01 ET
|
Ocean Biomedical, Inc.
Ocean Biomedical’s Anti-CHI3L1 patent coverage includes multiple methods of use for targeting a broad range of Cancers that include Lung Cancer, Glioblastoma, Prostate Cancer, Melanoma, and Breast...
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company’s Malaria Treatment and Prevention Platforms
August 27, 2024 08:01 ET
|
Ocean Biomedical, Inc.
Providence, RI, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ:OCEA) announced today that its Scientific Co-founder Dr. Jonathan Kurtis, MD, PhD, has been issued a key U.S. patent for...
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
August 23, 2024 16:30 ET
|
Ocean Biomedical, Inc.
PROVIDENCE, Rhode Island, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on August 19, 2024, it received a notice from The Nasdaq Stock Market LLC...
Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024
June 05, 2024 07:01 ET
|
Ocean Biomedical, Inc.
Providence, RI, June 05, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research...
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
May 30, 2024 07:44 ET
|
Ocean Biomedical, Inc.
PROVIDENCE, Rhode Island, May 30, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on May 22, 2024, it received a notice from The Nasdaq Stock Market...
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K
April 24, 2024 16:51 ET
|
Ocean Biomedical, Inc.
PROVIDENCE, Rhode Island, April 24, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on April 18, 2024, it received a notice from The Nasdaq Stock Market...
Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL
March 28, 2024 08:01 ET
|
Ocean Biomedical, Inc.
Providence, RI, March 28, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research...
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
November 29, 2023 17:41 ET
|
Ocean Biomedical, Inc.
PROVIDENCE, Rhode Island, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on November 22, 2023, it received a notice from The Nasdaq Stock Market...
Ocean Biomedical (NASDAQ: OCEA) Announces Positive Preclinical Oncology Data for VRON-0300, Presented at SITC 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion Therapeutics
November 14, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Providence, Rhode Island, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company working to accelerate the development of compelling discoveries from...